Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.49 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.49 |
| ▸ | GRM5 | P41594 | 6/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27045980 | 0.86 | PARP10 (0.43) | PARP10PARP11GRM5PARP1PDPK1 | |
| SCHEMBL27046248 | 0.83 | PARP10 (0.54) | PARP10PARP11GRM5PARP1GABRG2 | |
| SCHEMBL22686990 | 0.80 | GRM5 (0.49) | PARP10PARP11GRM5PARP1GABRG2 | |
| SCHEMBL29438691 | 0.80 | PARP10 (0.36) | PARP10PARP11GRM5PARP1TDP2 | |
| SCHEMBL27046075 | 0.77 | PARP10 (0.49) | PARP10PARP11PARP1PDPK1 | |
| SCHEMBL29438642 | 0.77 | PARP10 (0.49) | PARP10PARP11PARP1PDPK1 | |
| SCHEMBL31016159 | 0.77 | PARP10 (0.52) | PARP10PARP11GRM5PARP1PDPK1 | |
| SCHEMBL14571335 | 0.77 | TDP2 (0.59) | PARP10PARP11GRM5PARP1PDPK1 | |
| SCHEMBL29946459 | 0.74 | PKM (0.45) | — | |
| SCHEMBL8323443 | 0.72 | GRM5 (0.67) | PARP10PARP11GRM5PARP1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621207-B | Compound serving as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-114195764-B | Compound serving as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-4215524-A1 | COMPOUND SERVING AS THYROID HORMONE BETA RECEPTOR AGONIST AND USES OF COMPOUND | Sunshine Lake Pharma Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| CN-114621207-A | Compound as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2022057845-A1 | COMPOUND SERVING AS THYROID HORMONE β RECEPTOR AGONIST AND USES OF COMPOUND | 广东东阳光药业有限公司 | 2022-03-24 | — | — | WO | disclosed |
| CN-114195764-A | Compound as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | PARP10 4291/4885PARP11 4606/4885GRM5 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.